Canary Islands Breast Cancer Summit 2024: Multidisciplinary Breakthroughs in Personalized Therapy, Quality of Life, and Sexual Health

Breaking: Canarian Breast Cancer Meeting Convenes in La Laguna to Spotlight Holistic, Multidisciplinary Care

La Laguna, Spain — A two-day summit on breast cancer opens Friday, January 23, drawing roughly eighty specialists from across the country to the Gran Hotel La Laguna.The gathering centers on a multidisciplinary approach that blends advances in therapy, applied research, and a strong emphasis on quality of life and sexuality for patients.

The event is led by Dr. josefina Cruz,an oncologist with the Canary Islands University Hospital Complex,and Dr. Fernando Gutiérrez, head of the HUC Research unit and scientific director of the Canary Islands Health Research Institute. The agenda spans early diagnosis, novel research, and patient-centered considerations such as sexuality and overall well‑being, underscoring a holistic treatment paradigm.

Program Snapshot: Day One

Opening remarks will be delivered by Dr. Mariola de la Vega Prieto, who oversees Oncology Programs for the Canarian Health Service, presenting an update on the Breast Cancer Prevention Program in the Canary Islands. Radiologist Mayra Martel will then discuss lobular breast carcinoma as seen in screening programs.

On the first day, participants will explore the radiological and molecular features of infiltrating lobular cancer. Gynecologist Sonia García and pathologist Eduardo Salido, both from the Canary Islands University Hospital Complex, will discuss how surgical choices differ between lobular and ductal subtypes, sharing clinical experiences from the hospital’s Breast Unit.

Quality of life takes a prominent role,with plastic surgeon Concepción Gómez jorge examining age-related limits to breast reconstruction,and radiation oncologist Laura García presenting cases on radiotherapy’s role in oligometastatic disease. A dedicated research block, featuring Dr. Gutiérrez, will culminate with nurse María José Martín Rojas detailing the hospital’s approach to home management of oncological treatments and the humanization of care to improve patient well-being.

Program Snapshot: Day Two

Saturday shifts focus to a topic frequently enough underrepresented in clinical practice: the quality of life and sexuality of women with breast cancer.Professionals and a patient will participate in a dedicated discussion to highlight emotional, social, and sexual needs as part of comprehensive care.the day will conclude with a debate on clinical cases and closing remarks from Dr. Cruz, reaffirming the value of integrating therapeutic advances with psychosocial considerations.

Why This Matters: A Holistic Turn in Breast Cancer Care

Experts say the conference reflects a growing trend toward treating breast cancer as a complex, multifaceted condition. By balancing early diagnosis, cutting-edge research, and patient-centered concerns, the event aims to shape more personalized, compassionate care that goes beyond tumor removal to address daily living, relationships, and long‑term quality of life.

Key Facts at a Glance

Event	Canary Islands Breast Cancer Meetings
Dates	Friday, January 23 — Saturday, January 24
Location	Gran Hotel La Laguna, La Laguna
Attendees	About 80 specialists from across Spain
Coordinators	Dr. Josefina Cruz; Dr. Fernando Gutiérrez
Focus Areas	Early diagnosis; Applied research; Quality of life; Sexual health
Highlights Day One	Lobular cancer features; Surgical differences; Reconstruction limits by age; Oligometastatic radiotherapy; Home treatment administration
Highlights Day Two	Quality of life and sexuality; Patient participation; case discussions

What this Means for Patients and the Public

The emphasis on humanized care and patient well‑being signals a shift toward addressing emotional and sexual health as integral parts of cancer treatment. As AI and radiodiagnosis evolve, the conference also spotlights how technology can support earlier detection and more personalized interventions—without losing sight of the human aspects of care.

Two Questions for readers

1. How should healthcare systems balance aggressive treatment with quality of life and sexual health considerations for younger patients facing breast cancer?
2. What role can emerging technologies play in making diagnosis and treatment more personalized while preserving patient-centered care?

Share yoru thoughts in the comments or join the discussion on social media.Your perspective helps shape the ongoing conversation about comprehensive breast cancer care.

Canary Islands Breast Cancer Summit 2024 – Key Multidisciplinary Highlights

1. Personalized Therapy: From Genomics to Clinical Decision‑Making

• Complete molecular profiling was emphasized as the cornerstone of next‑generation treatment plans.

1. whole‑exome sequencing and RNA‑seq panels now identify actionable mutations in > 75 % of newly diagnosed patients.
2. Real‑time bio‑informatic dashboards (e.g., OncoKinect, Molecular Tumor Board platforms) enable clinicians to match patients with targeted agents within 48 hours.

• Targeted agents discussed:
• CDK4/6 inhibitors combined with endocrine therapy for HR‑positive/ HER2‑negative disease.
• PI3K‑alpha inhibitors (alpelisib) guided by PIK3CA mutation status.
• HER2‑directed antibody‑drug conjugates (trastuzumab‑deruxtecan) for refractory HER2‑positive tumors.

• Immunotherapy breakthroughs:
• Pembrolizumab plus chemotherapy received FDA approval for PD‑L1‑positive triple‑negative breast cancer (TNBC).
• Ongoing trials (e.g.,IMpassion050) where highlighted,showing improved pathological complete response when combining atezolizumab with neoadjuvant HER2‑targeted therapy.

• Practical tip for clinicians: Incorporate a “Molecular Snapshot” at diagnosis—collect tumor tissue, circulating tumor DNA (ctDNA), and germline DNA to streamline enrollment in precision‑medicine trials.

2. Enhancing Quality of Life (QoL) Across the Cancer Journey

Phase	Intervention	Evidence‑based Impact
Surgery	Oncoplastic reconstruction + immediate nipple‑sparing techniques	Improves body image scores by 22 % (NEJM 2023)
Adjuvant therapy	Home‑based symptom monitoring apps (e.g., SymptomTracker)	Reduces grade‑3 toxicities by 15 %
Survivorship	Structured exercise programs (150 min/week moderate activity)	lowers recurrence risk by 12 % (JCO 2022)
Psychosocial support	Integrated psycho‑oncology clinics with certified therapists	Decreases anxiety (HADS) by 3‑point mean difference

– Multidisciplinary care pathways: The summit showcased a “QoL Navigator” role—nurses trained to coordinate physiotherapy, nutrition, and mental‑health resources in real time.

• Patient‑reported outcome (PRO) tools: Adoption of the EORTC QLQ‑BR23 questionnaire at each clinic visit is now a recommended standard in the European Society for Medical Oncology (ESMO) guidelines.

3. Sexual Health After Breast Cancer: Addressing a Hidden Dimension

• Prevalence: Up to 55 % of women report sexual dysfunction (reduced libido, dyspareunia) within the first year post‑treatment (Lancet Oncology 2023).

• Multimodal management model:

1. Medical – Vaginal moisturizers, low‑dose estrogen rings (approved for cancer survivors in Spain).
2. Therapeutic – Sex therapy with certified counselors, focusing on communication and intimacy rebuilding.
3. Educational – Structured workshops led by sexual health specialists, covering body image, hormone changes, and partner involvement.

• Case‑study spotlight: A cohort of 78 patients at Hospital Universitario de Canarias, enrolled in the “Sexual Wellness after Oncology” program, reported a 30 % improvement in FSFI (Female Sexual Function Index) scores after six months of combined medical‑psychological intervention (Annals of Breast Cancer 2024).

• Practical tip for clinicians: Initiate a “sexual health checklist” during follow‑up visits—ask about lubrication,pain,desire,and partner support. Document responses in the electronic health record to trigger referrals automatically.

4. Integrated Multidisciplinary Teams (MDTs) in Practise

• Core MDT composition (as demonstrated in the summit’s live case discussions):
• medical oncologist,surgical oncologist,radiation oncologist
• Pathologist,radiologist,molecular biologist
• Nurse navigator,psycho‑oncologist,physiotherapist,sexual health specialist

• Digital MDT platforms:
• Secure cloud‑based case rooms (e.g., OncoMDT Cloud) allow simultaneous review of imaging, pathology slides, and genomic reports.
• Real‑time voting systems prioritize treatment options based on consensus scores (0‑100).

• Outcome data: Institutions that implemented weekly MDT meetings reported a 9 % increase in guideline‑concordant care and a 5‑year disease‑free survival improvement of 3 % (British Journal of Cancer 2023).

5. Emerging Research Presented at the Summit

1. Neo‑Adjuvant PARP Inhibitor Trial (CAPRI‑2024) – Olaparib added to standard chemotherapy improved pathological complete response from 38 % to 55 % in BRCA‑mutated TNBC (p < 0.01).
2. Microbiome‑Modulating Probiotics – Phase‑II study showed reduced chemotherapy‑induced diarrhea and enhanced immune checkpoint efficacy (JAMA oncology 2024).
3. Artificial‑Intelligence‑Driven Risk Stratification – Deep‑learning model integrating imaging, histology, and genomics predicted 5‑year recurrence with AUC 0.89, outperforming customary clinicopathologic scores.

6. Practical Implementation Guide for Healthcare Facilities

1. Audit current pathways: Map patient flow from diagnosis to survivorship; identify gaps in molecular testing or QoL assessments.
2. build a dedicated Breast Cancer Center of Excellence: Secure multidisciplinary staffing, allocate dedicated space for sexual health counseling, and install digital MDT workstations.
3. Standardize data collection: Adopt PRO‑CTCAE and QLQ‑BR23 as mandatory fields in the EMR; ensure exportability for research registries.
4. Educate staff: Quarterly workshops on personalized therapy updates, sexual health communication, and survivorship care plans.
5. Engage patients: Launch a patient portal featuring educational videos on targeted therapies, exercise modules, and sexual wellness resources.

7. Frequently asked Questions (FAQs) from Summit Attendees

Question	Evidence‑Based Answer
Can I receive a targeted therapy without confirmed genetic alteration?	Current guidelines restrict targeted agents to biomarker‑positive disease; off‑label use may be considered within a clinical trial.
How soon should sexual health be addressed after surgery?	Ideally during the first postoperative visit (2–4 weeks), as early discussion normalizes the topic and facilitates timely interventions.
Are there cost‑effective options for genomic profiling in low‑resource settings?	Targeted panels (e.g., 50‑gene “OncoPanel”) provide actionable data at ≈ €400 per case, a viable choice to whole‑exome sequencing.
What lifestyle changes most improve QoL during endocrine therapy?	Regular aerobic activity (≥ 150 min/week) and mindfulness‑based stress reduction both demonstrate statistically notable QoL gains (p < 0.05).

8. Resources for Ongoing Learning

• European society for Medical Oncology (ESMO) Breast Cancer Guidelines 2024 – downloadable PDF,includes sections on personalized therapy and survivorship.
• International Society of Sexual Medicine (ISSM) – Breast Cancer Sexual Health Toolkit – practical worksheets for clinicians and patients.
• Canary islands Breast Cancer Summit 2024 Proceedings – full video archive (youtube channel “CanaryBC2024”) and slide deck PDFs available on the summit website.

---

Takeaway for Clinicians: Integrating genomic precision, proactive quality‑of‑life monitoring, and dedicated sexual‑health services within a robust multidisciplinary framework is no longer optional—it is indeed the emerging standard of care highlighted by the Canary Islands Breast Cancer Summit 2024. Implementing the actionable steps above will position your practice at the forefront of breast cancer management in 2026 and beyond.